A) Incidence of De Novo, Secondary, and Therapy-Related Acute Myeloid... | Download Scientific Diagram
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 - Modern Pathology
Trends in acute myeloid leukaemia in Western Australia over time: Improved outcomes with contemporary management | Tasman Medical Journal
Outcome of patients with either de novo or secondary AML after alloSCT... | Download Scientific Diagram
Secondary vs de novo acute myeloid leukemia
Biology of secondary leukemia
Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice - Christin B. DeStefano, Christopher S. Hourigan, 2018
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
Frontiers | Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells
IJMS | Free Full-Text | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML
Acute Myeloid Leukemia | Oncohema Key
JCM | Free Full-Text | Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling
What is AML? | MDS Foundation
Recurrent mutation groups in de novo AML. Genes recurrently mutated in... | Download Scientific Diagram
Haematologica August 2021
Key Topic Videos | MYLOTARG®▽(gemtuzumab ozogamicin) | PfizerPro UK
Mutational variation in de-novo and secondary acute myeloid Leukemia.... | Download Scientific Diagram
Secondary acute myeloid leukemia
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst - ScienceDirect
Common mutations in de novo and secondary AML. A number of clonal blood... | Download Scientific Diagram
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study | Blood Cancer Journal
SocforHemepath on Twitter: "Another new provisional entity in the 2017 WHO: Acute Myeloid Leukemia with BCR-ABL1. This is a type of de novo AML, not to be confused with the blast phase
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics | Leukemia
